Business news, market intelligence, and global industry analysis.
The Latest

Cipla gets FDA approval for generic version of Novartis’ Durezo

bySrinath
August 12, 2021
Total
0
Shares
0
0
0

Cipla Limited said that it has secured final approval for its abbreviated new drug application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the US Food and Drug Administration (FDA).

Difluprednate Ophthalmic Emulsion 0.05% is a generic therapeutic equivalent version of Novartis Pharmaceutical’s Durezo.

The drug is indicated in the US for the treatment of inflammation and pain resulting from ocular surgery, and treatment of endogenous anterior uveitis.

Cipla gets FDA approval for generic version of Novartis’ Durezo
Cipla gets FDA approval for generic version of Novartis’ Durezo. Image courtesy of Clker-Free-Vector-Images from Pixabay.

As per IQVIA (IMS Health), Durezol had sales of nearly $106 million in the US for the 12-month period ending June 2021.

Cipla said that Difluprednate Ophthalmic Emulsion 0.05% will be available for shipping shortly.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Novartis acquires kidney disease innovator Chinook Therapeutics
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes

German drugmaker Boehringer Ingelheim will initiate Phase 2 clinical trial of dual-acting GLP-1/glucagon agonist BI 456906 in obesity and diabetes in late 2019. The compound in-licensed from Zealand Pharma is derived from the natural gut hormone oxyntomodulin and activates both the GLP-1 and glucagon receptors to control metabolic activities. The dual agonist BI 456906 with […]

The post Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes appeared first on PharmaNewsDaily.com.

bySrinath